C-Abl tyrosine kinase inhibitory compound embodiments and methods of making and using the same

US11649218B2 · kind B2 · utility

Assignees

• The United States of America, as represented by the Secretary, Department of Health and Human Services · US
• PONTIFICIA UNIVERSIDAD CATOLICA DE CHILE · CL

Inventors

• Juan Jose Marugan · Gaithersburg, US
• Marc Ferrer · Potomac, US
• Noel Terrence Southall · Bethesda, US
• Andres E. Dulcey · Gaithersburg, US
• Xin Hu · Chestertown, US
• Christopher R. Dextras · Frederick, US
• Daniel C. Talley · Baltimore, US
• Alejandra Alvarez · Santiago, CL
• Silvana Zanlungo · Santiago, CL
• Rommy M. Von Bernhardi · Santiago, CL

Key dates

• Filing date: Mar 8, 2019
• Grant date: May 16, 2023
• Expiry date: Mar 8, 2039

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07F7/0812
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Disclosed herein are embodiments of a compound that inhibits c-Abl tyrosine kinase (also referred to herein as “c-Abl”). The compound embodiments described herein are novel c-Abl inhibitors that can bind to c-Abl at an allosteric site and inhibit its activity in various pathways. The compound embodiments also are capable of crossing the blood brain barrier and therefore are useful in inhibiting c-Abl activity as it affects pathways and/or proteins in the brain. The compound embodiments described herein are effective therapeutic agents for treating diseases involving c-Abl, such as cancers, motor neuron diseases, and neurodegenerative diseases. Also disclosed herein are embodiments of methods for making and using the c-Abl inhibitory compound embodiments.